Dixestivo
Servizo
Hospital Universitario Virgen del Rocío
Sevilla, EspañaPublicacións en colaboración con investigadores/as de Hospital Universitario Virgen del Rocío (94)
2024
-
Advanced fibrosis associated with non-alcoholic steatohepatitis (NASH) in Spain: results of a Delphi study
Gastroenterologia y Hepatologia, Vol. 47, Núm. 4, pp. 337-346
-
Baiona's Consensus Statement for Fecal Incontinence. Spanish Association of Coloproctology
Cirugia Espanola, Vol. 102, Núm. 3, pp. 158-173
-
Characterizing Hepatitis Delta in Spain and the gaps in its management
Gastroenterologia y Hepatologia
-
Combination of granulocyte–monocyte apheresis and tofacitinib: Multicentre and retrospective study
Gastroenterologia y Hepatologia, Vol. 47, Núm. 7, pp. 727-733
-
Combination of granulocyte–monocyte apheresis and ustekinumab: Multicentre and retrospective study
Gastroenterologia y Hepatologia
-
Development and Validation of a Scoring System to Predict Response to Obeticholic Acid in Primary Biliary Cholangitis
Clinical Gastroenterology and Hepatology, Vol. 22, Núm. 10, pp. 2062-2074.e11
-
Effectiveness and safety of azathioprine for inflammatory pouch disorders: results from the RESERVO study of GETECCU
Therapeutic Advances in Gastroenterology, Vol. 17
-
GEMA-Na and MELD 3.0 severity scores to address sex disparities for accessing liver transplantation: a nationwide retrospective cohort study
eClinicalMedicine, Vol. 74
-
LiverAI: New tool in the landscape for liver health
Gastroenterologia y Hepatologia, Vol. 47, Núm. 6, pp. 646-648
-
Longitudinal outcomes of obeticholic acid therapy in ursodiol-nonresponsive primary biliary cholangitis: Stratifying the impact of add-on fibrates in real-world practice
Alimentary Pharmacology and Therapeutics, Vol. 59, Núm. 12, pp. 1604-1615
-
Persistence, effectiveness and safety of ustekinumab and vedolizumab therapy for complex perianal fistula in Crohn's disease: The HEAL study from GETECCU
Digestive and Liver Disease
-
Real-life effectiveness of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients previously treated with sofosbuvir/velpatasvir or glecaprevir/pibrentasvir
Alimentary Pharmacology and Therapeutics, Vol. 60, Núm. 2, pp. 201-211
-
Recommendations for the future management of thrombocytopenia in patients with liver cirrhosis: A modified RAND/UCLA appropriateness method
Gastroenterologia y Hepatologia, Vol. 47, Núm. 1, pp. 32-50
-
Rituximab is a safe and effective alternative treatment for patients with autoimmune hepatitis: Results from the ColHai registry
Liver International, Vol. 44, Núm. 9, pp. 2303-2314
-
The biochemical pattern defines MASLD phenotypes linked to distinct histology and prognosis
Journal of Gastroenterology, Vol. 59, Núm. 7, pp. 586-597
2023
-
Benefits of Paediatric to Adult Transition Programme in Inflammatory Bowel Disease: The BUTTERFLY Study of GETECCU and SEGHNP
Journal of Clinical Medicine, Vol. 12, Núm. 14
-
Effectiveness and safety of once-daily tacrolimus formulations in de novo liver transplant recipients: The PRETHI study
Clinical Transplantation, Vol. 37, Núm. 12
-
Oportunistic diagnosis based on age and hepatitis C virus clearance: an essential step to improve the overall health of the liver
Revista Espanola de Enfermedades Digestivas, Vol. 115, Núm. 3, pp. 128-132
-
Real-World Evidence of Tofacinitib in Ulcerative Colitis: Short-Term and Long-Term Effectiveness and Safety
American Journal of Gastroenterology, Vol. 118, Núm. 7, pp. 1237-1247
-
Real-world outcomes of switching from adalimumab originator to adalimumab biosimilar in patients with inflammatory bowel disease: The ADA-SWITCH study
Alimentary Pharmacology and Therapeutics, Vol. 58, Núm. 1, pp. 60-70